Boryung Pharma to commercialize Aplidin from Spain

05:37
[Robert J. Fouser] AI changes rationale for learning languages
05:30
[Editorial] Face up to Trump
20:52
Gov't to spend W95b to support reforms at 41 public hospitals in H1
18:37
[Today’s K-pop] Stray Kids go gold in US with ‘Maniac’
18:15
KASA chief vows full support for private-led space missions
18:15
Seoul alerts overseas missions to NK terror threats
18:13
Medical schools to increase up to 1,509 seats for 2025
18:04
Yoon's office to set up task force to keep growth momentum
17:27
Public backlash against division of Gyeonggi Province under 'corny' name
16:48
Inflation eases in April, continues bumpy ride

Boryung Pharma to commercialize Aplidin from Spain

Oct. 4, 2016 - 14:14 By 윤정현

[DISCLOSURE] Boryung Pharmaceutical (003850) reported on Oct. 4 that it has signed a technology introduction contract with PharmaMar of Spain for rights to launch and commercialize Aplidin, a treatment option for multiple myeloma, in Korea.

By Yun Jeong-hyeon (clareyun@heraldcorp.com)

윤정현

Most Popular

1

Exports to US reach all-time high, widen gap with China
2

Trump rekindles criticism: US forces defending 'wealthy' S. Korea 'free of charge'
3

[Music in drama] Rekindle a love that slipped through your fingers
4

S. Korea discussed possible participation in AUKUS Pillar 2 with Australia: defense minister
5

[New faces of Assembly] Architect behind ‘audacious initiative’ believes in denuclearized North Korea
6

Opposition-led Assembly unilaterally passes bill to probe Marine's death